Trials
1 active
8 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “potent, selective, first-in-class, small molecule oral inhibitor of FAP and is being developed for the treatment of CLDs with advanced hepatic fibrosis including cirrhosis.”In the company’s words, NCT07610837 on ClinicalTrials.gov
- Tested for
- Liver Fibrosis, Hepatic Cirrhosis
- Main trialPhase 2
- “The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.”In the company’s words, NCT07610837 on ClinicalTrials.gov
- Other names
- Active IMP
Other drugs for Liver Fibrosis
- ElafibranorIpsen · Phase 3
- ResmetiromMadrigal Pharmaceuticals, Inc. · Phase 3
- Saroglitazar MagnesiumZydus Therapeutics Inc. · Phase 3
- HydronidoneBeijing Continent Pharmaceutical Co, Ltd. · Phase 3
- LinerixibatGSK · Phase 3
- SeladelparGilead (Kite) · Phase 3
Coming up1
- 7 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 7 Jul 2027 | Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | |
| Phase 2Completed | 28 Jul 2025 | A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. | |
| Phase 1Completed | 23 Apr 2025 | A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants | |
| Phase 1Completed | 18 Jul 2025 | A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine | |
| Phase 1Completed | 18 Jul 2025 | A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants | |
| Phase 1Completed | 24 Aug 2025 | A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants | |
| Phase 1Completed | 4 Sep 2025 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 | |
| Phase 1Completed | 2 Jul 2026 | The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026